Jane Street
ATRA icon

Jane Street’s Atara Biotherapeutics ATRA Stock Holding History

Jane Street’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,400
Closed -$321K – 9100
2022
Q3 		$321K Buy
+3,400
New +$382K ﹤0.01% 7470
2021
Q1 		– Sell
-572
Closed -$281K – 9063
2020
Q4 		$281K Buy
+572
New +$264K ﹤0.01% 6501

Other funds holding ATRA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street's ATRA Position: Q1 2026 in Review

Jane Street increased its Atara Biotherapeutics (ATRA) stake by 142% in Q1 2026, buying an estimated $121K and bringing the position to 33,870 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #10334.

Jane Street first reported a position in ATRA in Q3 2015 and has held it in 21 quarters since. The position peaked at $1.4M in Q3 2020. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

  • Jane Street held 33,870 shares of Atara Biotherapeutics worth $160K as of Q1 2026.
  • Jane Street bought 19,880 Atara Biotherapeutics shares in Q1 2026, an estimated $121K.
  • Atara Biotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10334 holding.
  • Jane Street first reported a position in Atara Biotherapeutics in Q3 2015 and has held it in 21 quarters since.
  • Jane Street's Atara Biotherapeutics position peaked at $1.4M in Q3 2020.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.